Abstract 31P
Background
Cervical cancer is a major public health concern as it is the fourth leading cause of cancer-related fatalities among women. India has the highest incidence of cervical cancer worldwide. Omics diagnostic tools, particularly proteomics, are helpful in tracking the development of the disease as cancer therapy continues to shift towards precision medicine. The primary objective of this study was to explore the global protein expression patterns of cervical cancer in the Indian population for the first time to encourage the application of current diagnostic and treatment modalities.
Methods
We employed MS-based quantitative global (Label-free quantification or LFQ) and targeted proteomics (multiple reaction monitoring or MRM) in bio-banked tissue samples of cervical cancer and healthy tissue (Control=8, Tumor=7; 6 Paired, 2 unpaired). With a very small amount of starting tissue material (10-12 mg) proteomic biomarker profiling was conducted as pilot research. Finally, a complex set of protein candidates belonging to the mRNA splicing and MTORC1 signaling pathway has been confirmed and refined at the peptide level by MRM assay.
Results
We observed proteins belonging to the mRNA processing and maturation via alternative splicing pathway were overexpressed in cervical tumors. Heterogeneous nuclear ribonucleoproteins (hnRNPs), the components of spliceosome complex regulate both constitutive and alternative splicing in tumors. We found at least 5 hnRNPs and few HSP (heat-shock proteins) to be significantly overexpressed in tumors via global proteomics. Validation of candidate hnRNPs (HNRNPA2, HNRNPA1) and Heat-shock proteins (HSPs) were done by targeted proteomics. Furthermore, we developed a comprehensive panel of peptides which can be investigated to check for the effectiveness of tumour development which pave the way towards a better diagnosis.
Conclusions
This foundation study, for the very first time, facilitated the development of a panel of proteomic biomarkers of Cervical cancer in Indian population. We propose that a set of these markers including HNRNPs can be further useful for the development of a complete biomarker panel for cervical cancer diagnosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Indian Institute of Technology, Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract